Infertility Clinical Trial
Official title:
The Effectiveness of a Freeze All Protocol Versus Fresh Embryo Transfer in Women Undergoing In-vitro Fertilization (IVF) - Intracytoplasmic Sperm Injection (ICSI)
To compare the effectiveness of freeze-all and subsequent frozen embryo transfer (freeze all protocol) with fresh embryo transfer (fresh ET).
All patients undergoing in-vitro fertilization (IVF) will be treated with GnRH antagonist
protocol. Recombinant Follicle-stimulating hormone (FSH) will be given on day 2 or day 3 of
menstrual cycle for 5 days. The starting dose is individualized for each patient based on the
following criteria: Anti-Mullerian Hormone (AMH) < 0.7 ng/ml, dose 300 IU/day, AMH 0.7 -2.1
ng/ml, dose 225 IU/day, AMH > 2.1 ng/ml, dose 150 IU/day. After that, investigators can
titrate the dose based on their clinical judgment. Follicular development will be monitored
by ultrasound scanning and measurement of estradiol, progesterone starting on day 5 of
stimulation. Scanning and hormonal measurement will be repeated every 2 to 3 days, depending
on the size of follicles. Antagonist is routinely used on day 5 until the day of Human
chorionic gonadotropin (hCG). Criteria for recombinant hCG (6,500 IU) administration is the
presence of at least three leading follicles of 17 mm. Oocyte retrieval is performed 36 hours
after recombinant hCG administration.
We will measure progesterone levels during stimulation on the day 5 and day 7, as well as on
the day of oocyte triggering.
Insemination will be performed by using intracytoplasmic sperm injection, 3 - 4 hours after
oocyte retrieval. Only matured oocytes are inseminated. Fertilization are performed under
inverted microscope at period of 16-18 hours after insemination.
On day 3, endometrium thickness will be measured and embryo evaluation will be performed at
fixed time point 68±1 hours after fertilization, using Istanbul consensus. After grading
embryo, eligible patients will be invited to participate in the study. Written consent will
be obtained from each patient for participation into the study. Patients will be randomized
into 2 groups fresh embryo transfer and freeze-all. Randomization will be done by third party
via telephone, using a computer-generated random list, with block size of 2, 4, 8.
Study Procedures
Freeze all group
All grade 1 and grade 2 embryos were cryopreserved using vitrification method. In the next
cycle, endometrium will be prepared by using estradiol orally, starting from day 2-3 of
menstrual cycle. When endometrium thickness reaches 8mm or more, patients start to use
progesterone vaginally. Embryo transfer is performed 3 days after using progesterone. On the
day of embryo transfer, maximum two embryos will be thawed. Two hours after thawing,
surviving embryos will be transferred into the uterus under ultrasound guidance. Luteal-phase
support is done with estradiol 8mg/day and vaginal progesterone 800mg/day until 7th week of
gestation.
Fresh ET group
In fresh ET group, maximum 2 embryos will be transferred into the uterus under ultrasound
guidance. The remain grade 1 and 2 embryos will be frozen. Luteal phase support is done with
estradiol 8mg/day and vaginal progesterone 800mg/day until 7th week of gestation.
In both of groups, serum hCG was measured 2 weeks after embryo transferred, and if positive,
an ultrasound scan of the uterus was performed at gestational weeks 7 and 12.
METHODS
SAMPLE SIZE CALCULATION
At IVFMD, the current ongoing pregnancy rate (with 2 embryos transferred) is 30%. To show an
improvement in the freeze-all group of 10% (from 30% to 40%), it was calculated that 712
couples (356 in each group) would be needed (power 0.80, alpha-error 5%, two-sided test). To
account for an estimated loss to follow-up rate of 10%, the number of patients needed was
defined as 780 (390 patients per group).
STUDY ENDPOINTS
Primary endpoint
Ongoing pregnancy (OP). Ongoing pregnancy is explained as a pregnancy with positive heart
beat beyond 12 weeks of gestation (twins is count as a single pregnancy).
Secondary endpoints
- Implantation rate: defined as the number of gestational sacs per number of embryos
transferred.
- Clinical pregnancy: defined as the presence of a gestational sac seen by transvaginal
sonography 7 weeks after embryo replacement.
- Multiple pregnancy rate. defined as a pregnancy with two or more fetal heart beats by
transvaginal sonography at 7 weeks of gestation.
- Vanishing twins: defined as a pregnancy with tow or more gestational sacs or positive
heart beats at 7 weeks of gestation, but only one at 12 weeks' gestation.
Treatment complications
- Ovarian hyperstimulation syndrome (OHSS): classified as moderate or severe by RCOG
guidelines [Green-top Guideline No. 5, 2006].
- Miscarriage: defined as the complete loss of a clinical pregnancy prior to 24 weeks'
gestation.
- Ectopic pregnancy: defined as the ectopic nidation of a pregnancy, confirmed by
sonography or laparoscopy.
Obstetric outcomes
- Live birth rate, defined as the birth of a newborn, irrespective of the duration of
gestation, that exhibits any sign of life, such as respiration, heart-beat, umbilical
pulsation or movement of voluntary muscles.
- Gestational age at delivery.
- Birth weight.
- Congenital malformations.
- Macrosomia (birth weight >90th percentile)
- Small for gestational age (birth weight <10th percentile)
- NICU admittance
- Perinatal mortality: defined as the death of a fetus or infant from 24 weeks of
gestation to the end of the neonatal period of 4 weeks after birth.
Pregnancy complications
- Pregnancy-associated hypertension: defined as a diagnosis of pregnancy-induced
hypertension made after the 20th week of gestation, excluding intraoperative blood
pressures and intrapartum systolic pressures, with systolic blood pressure of ≥140 mmHg
or diastolic pressure of ≥90 mmHg on two occasions 2 hours apart, or a severely elevated
single blood pressure measurement that led to treatment with an antihypertensive
medication.
- Preeclampsia: defined as any type of hypertension combined with proteinuria (total
protein excretion of 300 mg or other organ involvement [such as renal insufficiency,
liver involvement, neurological or hematological complications, uteroplacental
dysfunction, or fetal growth restriction]) according to the International Society of
Studies in Hypertension in Pregnancy.
- HELLP syndrome: defined as elevated liver enzyme levels (aspartate aminotransferase ≥100
U/L), thrombocytopenia (platelet count <100,000/mm3), elevated serum creatinine level
(≥1.5 mg/dL [132.6 μmol/L]) and/or hemolysis (hemoglobin <10 g/dL).
- Prematurity: defined as iatrogenic preterm birth at <32 weeks' gestation, spontaneous
preterm birth at <32 weeks' gestation; iatrogenic preterm birth at <37 weeks gestation;
spontaneous preterm birth at <37 weeks' gestation
- Antepartum hemorrhage: defined as bleeding from the genital tract in the second half of
pregnancy.
- Gestational diabetes mellitus: diagnosed using a 75g oral glucose tolerance test
(Fasting: 92 mg/dL [5.1 mmol/L]; 2 h: 153 mg/dL [8.5 mmol/L]) [American Diabetes
Association 2013].
Labor
Induction of labor
- Cesarean section
- Elective
- Suspected fetal distress
- Non-progressive labor
- Vaginal instrumental delivery
- Suspected fetal distress
- Non-progressive labor
- Peripartum increased blood loss (≥1000 mL)
SUBJECT INFORMED CONSENT A review of patient information should be done prior to enrolment to
determine preliminary eligibility according to patient inclusion and exclusion criteria. When
a patient signs an informed consent she is considered to be enrolled in the study.
WITHDRAWAL OF INDIVIDUAL PATIENTS Patients can leave the study at any time for any reason if
they wish to do so without any consequences for their treatment. The investigator can decide
to withdraw a subject from the study or urgent medical reasons.
STATISTICAL EVALUATION
Event rates will be calculated for dichotomous endpoints. These will be compared by
calculating relative risk and 95% confidence interval values. Between-group differences in
non-continuous variables will be assessed using the Fisher exact test. Continuous variables
will be reported as mean values ± standard deviation (SD) or as percentages. Between-group
differences in continuous variables will be assessed with the Student's t-test.
In a secondary analysis we will assess whether the biomarkers progesterone at triggering day
and endometrial thickness on day 3 after oocyte pick up can be used to identify patients in
whom the freeze all strategy is particularly effective. To do so, we will look for
interaction between progesterone or endometrial thickness and treatment effect.
A p-value <0.05 is defined as indicating a statistically significant difference. The analysis
will be done with R statistical package (R version 3.3.1).
INTERIM ANALYSIS
Interim analysis will be performed after recruitment of the first 400 patients. An
independent Data Safety Monitoring Committee (DSMC) will evaluate the data. A specific
stopping rule will not be formulated, but continuation of the study will depend on the advice
of the DSMC.
SAFETY REPORTING
The investigator will inform the subjects and the reviewing accredited medical research
ethics committee; if anything occurs, on the basis of which it appears that the disadvantages
of participation may be significantly greater than was foreseen in the research proposal. The
investigator will take care that all subjects are kept informed.
ADVERSE AND SERIOUS ADVERSE EVENTS All observed or volunteered adverse events, regardless of
treatment group or suspected causal relationship to intervention, will be recorded. Adverse
events are defined as any undesirable experience occurring to a subject during a clinical
trial, whether or not considered related to the intervention. All adverse events reported
spontaneously by the subject or observed by the investigator or his staffs will be recorded.
A serious adverse event is any untoward medical occurrence or effect that at any dose results
in death;
- is life threatening (at the time of the event);
- requires hospitalisation or prolongation of existing inpatients' hospitalisation;
- results in persistent or significant disability or incapacity;
- is a congenital anomaly or birth defect;
- is a new event of the trial likely to affect the safety of the subjects, such as an
unexpected outcome of an adverse reaction.
ETHICAL CONSIDERATIONS
RECRUITMENT AND CONSENT The subject should be given the time to read and understand the
statement herself before signing her consent and dating the document. The subject should
receive a copy of the written statement once signed.
PRIVACY ASPECTS Participating subjects will be registered by a 5-digit number. This personal
code will be on all forms retrieved from participants.
BENEFITS AND RISKS ASSESSMENT, GROUP RELATEDNESS There is insufficient evidence for a
rational policy in between the 2 strategies, freeze all or fresh ET. The potential benefits
of freeze all are higher pregnancy rate, with a lower incidence of ovarian hyperstimulation
syndrome (OHSS) and/or ectopic pregnancy. The potential harm would be time-consuming.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A |